Elanco Animal Health Incorporated · NYSE:ELAN
Elanco Animal Health — Investor Presentation (May 2025)
27 slides from Elanco Animal Health's investor presentation, May 2025
Slide 1: Enriching Life
Food and Companionship Enriching Life
Slide 2: Notices and Disclaimers
Investor Overview | May 2025 Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 ful
Slide 3: Touching nearly every person, every day
Touching nearly every person, every day
Slide 4: We Go Beyond: Transforming Animal Care
We Go Beyond Transforming Animal Care Helping pets live longer, healthier, more active lives. • From diabetes, to the deadliest disease in puppies, parvovirus, and many others Helping farmers improve animal health and wellbeing, and raise livestock more sustainably. • Increased production, reduced e
Slide 5: Elanco at a Glance
Investor Overview | May 2025 Elanco at a Glance Key Financial Metrics 2024 Results A Global, Independent Leader Reaching $4.439 B $910 M $0.91 Revenue Adj. EBITDA1 Adj. EPS1 the World’s Animals Diverse, Global Portfolio 2 5 Core Species 9 Blockbusters 200+ brands We provide medicines Pet health & fa
Slide 6: Elanco's Strategic Trajectory
Investor Overview | May 2025 Elanco’s Strategic 2025 & Beyond Trajectory 2021-2024 Poised for From a Pharma Division Sustainable Innovation Revenue Growth to a Global, Independent Leader Delivered & Multiple approved potential 2019-2021 Enhanced blockbusters and a Balanced Mix & Capabilities stabili
Slide 7: A Diverse, Experienced Leadership Team
Investor Overview | May 2025 A Diverse, Experienced Leadership Team One of the most seasoned Animal Health leadership teams with decades of industry experience Jeff Simmons Tim Bettington Dr. Ramiro Cabral Dr. Ellen de Brabander David Kinard President & Executive Vice President Executive Vice Presid
Slide 8: An Animal Health Leader Entering the Next Era
Investor Overview | May 2025 An Animal Health Leader Entering the Next Era Well-positioned to deliver sustainable revenue growth and meaningful long-term value ~$41B1 global animal health pharmaceutical industry across Pet Health Attractive, Growing Markets ($16B) and Farm Animal ($25B) with consist
Slide 9: Animal Health: Attractive, Growing Markets with Positive Long-Term Tailwinds
Investor Overview | May 2025 Animal Health: Attractive, Growing Markets with Positive Long-Term Tailwinds Pet Health Farm Animal $16B Global Industry1 $25B Global Industry1 Pet ownership and Protein demand growth globally “humanization” of pets driven by GDP and expanding a continued tailwind global
Slide 10: Elanco's Strategy to Deliver Value to All Stakeholders
Investor Overview | May 2025 Deliver consistent, high-impact Innovation • $660-$740 million annual new revenue from Innovation expected by 2025 1 • Target first-in-class, differentiation and big market spaces IPP: • Focus on maximizing life cycle management and refilling early-stage pipeline Po Inno
Slide 11: Focused on Delivering Consistent, High-Impact Innovation
Investor Overview | May 2025 n Po tio rtf a Innov olio Focused on Delivering Consistent, High-Impact Innovation Pr Customer oductivity With three clear parallel priorities for the R&D organization Pipeline Progression: Advance Pipeline Life Cycle Shifting to with Next Wave Management Launch Mode To
Slide 12: Seven Potential Blockbusters Expected to Fuel Revenue Growth in 2025 and Beyond
Investor Overview | May 2025 n Po tio Seven Potential Blockbusters Expected to Fuel rtf a Innov olio Customer Revenue Growth in 2025 and Beyond Pr oductivity Peak Sales Asset Market Focus Species Approval1 Launch2 Opportunity3 Commentary First-in-class; Combo clearance Experior U.S. Beef approval to
Slide 13: 2025 Innovation Sales Target Raised
Investor Overview | May 2025 2025 Innovation Sales Target Raised: Now Expected to $660-$740M Deliver an Incremental Q1 Actuals $198M $660-$740 Million $461M Q4 Actuals $140M Pet Big 6 Innovation Q1 Health early in launch $275M curve with portfolio $133M exceeding the $72M Farm corporate gross Animal
Slide 14: Accelerating Topline Growth Driven by Portfolio Diversity and Innovation
Investor Overview | May 2025 n Po tio rtf a Innov olio Accelerating Topline Growth Driven by Portfolio Diversity, Pr Customer oductivity Innovation Contribution and Key Growth Enablers Diversity Across Geography and Species Expected Revenue Trajectory Drives Durability1 Constant currency4 change yea
Slide 15: Successful, Purposeful Portfolio Expansion & Transformation
Investor Overview | May 2025 n Po io at rtf Innov olio Successful, Purposeful Portfolio Expansion & Transformation Customer Pr oductivit y Key acquisitions and bolt-ons since IPO 2019 2020 2021 Animal Health a pet therapeutics company a major acquisition of the animal health a biopharmaceutical comp
Slide 16: Completed Sale of Aqua Business
Investor Overview | May 2025 n Po io at rtf Innov olio Completed Sale of Aqua Business Customer Pr oductivit y Reinforces Commitment $1.3B Minimal EPS dilution to Larger Markets Purchase Price expected with strategy with Greater Earnings Received in cash, with Concentrating our strategic focus Poten
Slide 17: Global Pet Health Market Positioning
Investor Overview | May 2025 n Po tio rtf a Innov olio Global Pet Health Market Positioning Customer Strategic Framework Pr oductivity ` Pain & Other Vaccines1 Parasiticides Dermatology Therapeutics Vision Omnichannel offerings Differentiated entrant Broad portfolio for dogs Prevention with retail l
Slide 18: Pet Health: Established Strength, Innovating into Big Spaces
Investor Overview | May 2025 n Po io at rtf Innov olio Pet Health: Established Strength, Innovating into Big Spaces Customer Pr oductivit y Global US International $2.1B, 50% of Elanco $1.2B, 28% of Elanco $0.9B, 22% of Elanco Full portfolio including broad spectrum and over-the- Portfolio Strength
Slide 19: Global Farm Animal Market Positioning
Investor Overview | May 2025 n Po tio rtf a Innov olio Global Farm Animal Market Positioning Customer Strategic Framework Pr oductivity Efficiency & Disease Prevention Food Safety Sustainability Performance & Treatment Vision Market leading Trusted partners Partnering with Building new market portfo
Slide 20: Farm Animal: Diverse Base, Innovating into Sustainability
Investor Overview | May 2025 n Po io at rtf Innov olio Farm Animal: Diverse Base, Innovating into Sustainability Customer Pr oductivit y Global US International $2.3B, 50%1 of Elanco $0.8B, 19% of Elanco $1.5B, 31% of Elanco Cattle medicated feed additives (MFAs), poultry, Portfolio Strength Poultry
Slide 21: Financial Strength and Discipline Drive Improved Debt Profile
Investor Overview | May 2025 n Po tio rtf a Innov olio Financial Strength and Discipline Drive Improved Debt Profile Pr Customer oductivity Disciplined capital allocation strategy supports continued investment in the business and deleveraging Balance Sheet Strengthens Capital Allocation Priorities G
Slide 22: Optimized Manufacturing Footprint Supports Global Business
Investor Overview | May 2025 n Po io at rtf Innov olio Optimized Manufacturing Footprint Supports Global Business Customer Pr oductivit y Site consolidation has contributed to meaningful productivity savings; Positioned to deliver innovation pipeline Internal Fermentation Clinton, IN Nutritionals Te
Slide 23: Appendix
Investor Overview | May 2025 Appendix
Slide 24: Revenue Performance by Top Ten Countries
Investor Overview | May 2025 Full Year 2024 Organic CC Revenue Total % of Total Change1 Performance by United States $2,036 46% 3% Top Ten China $196 4% -3% Brazil $190 4% 9% Countries United Kingdom $159 4% 4% Italy $120 3% 5% Canada $118 3% 10% Mexico $117 3% 6% France $117 3% 11% Spain $88 2% 32%
Slide 25: Revenue Performance for Select Products
Investor Overview | May 2025 Full Year 2024 Revenue 2024 Revenue % of Total CC Change1 Performance for Select 2 $458 10% 2% Products $365 8% 10% $288 6% 16% $260 6% 8% 3 $221 5% 14% Note: Reported revenue in millions. Numbers may not add due to rounding. 1Constant Currency (CC) is a non-GAAP financi
Slide 26: Adjusted Income Statement Highlights
Investor Overview | May 2025 Full Year 2024 Adjusted1 Income Statement Highlights Including Impact from Aqua Divestiture $ millions, except per share values 2024 2023 Change ($)2 Change (%)2 Revenue $4,439 $4,417 $22 0% Cost of Sales $2,003 $1,929 $74 4% Adjusted Gross Profit $2,436 $2,488 $(52) (2)
Slide 27: 2025 Full Year Financial Guidance
Investor Overview | May 2025 2025 Full Year Financial February May Comments Guidance Revenue $4,445 - $4,510 $4,510 - $4,580 Revenue raise driven by FX Reported Net (Loss) $(25) - $7 $(35) - $(7) Income $ millions, except per share values Adjusted EBITDA1 $830 - $870 $830 - $870 Unchanged from prior
Elanco Animal Health — Investor Presentation (May 2025) on 6ix